FGI-106 tetrahydrochloride

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

FGI-106 tetrahydrochloride is active against Ebola, Rift Valley and Dengue Fever viruses with EC50s of 100 nM, 800 nM and 400-900 nM, respectively.?

FGI-106 tetrahydrochloride is active against Ebola, Rift Valley and Dengue Fever viruses with EC50s of 100 nM, 800 nM and 400-900 nM, respectively.?FGI-106 tetrahydrochloride also inhibits non-hemorrhagic fever viruses HCV and HIV-1 with EC50s of 200 nM and 150 nM, respectively.?FGI-106 tetrahydrochloride is a potent and broad-spectrum inhibitor with inhibitory activity against multiple viruses.(In Vitro):In cell-based assays, treatment with FGI-106 inhibits viral replication by divergent virus families, including positive and negative-strand RNA viruses.Treatment with 2 μM FGI-106 mediated a 4 log reduction in infectious viral titers relative to matched controls, with an EC90 for inhibition of viral killing of host cells (Vero E6 cells) estimated to be 0.6 μM.?(In Vivo):FGI-106??treatment decreases mortality from Zaire EBOV in a dose-dependent manner.

——

Others

Other Targets

——

——

——

1149348-10-6

604.5

C28H42Cl4N6

>98% (HPLC)

——

Cl.Cl.Cl.Cl.CN(C)CCCNc1cc(C)nc2c1ccc1c2ccc2c(NCCCN(C)C)cc(C)nc12

——

(-20℃)

With Ice Pack

≥ 2 years